Abstract:Intrahepatic cholangiocarcinoma (iCCA) has over the last 10-20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide. The significant increase in mortality rates from this primary hepatobiliary cancer, particularly over the past decade, has coincided with a rapidly growing interest among clinicians, investigators, and patient advocates to seek greater mechanistic insights and more effective biomarker-driven targeted approaches for managing and/or preventing this challenging liver cancer. In addition to discussing challenges posed by this aggressive cancer, this review will emphasize recent epidemiological, basic, and translational research findings for iCCA. In particular, we will highlight emerging demographic changes and evolving risk factors, the critical role of the tumor microenvironment, extracellular vesicle biomarkers and therapeutics, intertumoral and intratumoral heterogeneity, and current and emerging targeted therapies regarding iCCA. Specifically, recent evidence linking non-bile duct medical conditions, such as nonalcoholic fatty liver disease and nonspecific cirrhosis, to intrahepatic cholangiocarcinogenesis together with geographic and ethnic variation will be assessed. Recent developments concerning the roles played by transforming growth factor-β and platelet-derived growth factor D in driving the recruitment and expansion of cancer-associated myofibroblasts within cholangiocarcinoma (CCA) stroma as well as their therapeutic implications will also be discussed. In addition, the potential significance of extracellular vesicles as bile and serum biomarkers and therapeutic delivery systems for iCCA will be described. An integrated systems approach to classifying heterogeneous iCCA subtypes will be further highlighted, and recent clinical trials and emerging targeted therapies will be reviewed, along with recommendations for future translational research opportunities. Established international CCA networks are now facilitating collaborations aimed at advancing iCCA translational and clinical research.

[New Advances in the Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma].

Research advances in the clinical diagnosis of intrahepatic cholangiocarcinoma

Treatment of intrahepatic cholangiocarcinoma based on biological behavior

Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

The Research Situation and Progress in the Invasion and Metastasis Mechanism of Intrahepatic Cholangiocarcinoma

Treatment Progress of Intrahepatic Cholangiocarcinoma

[Surgical and Comprehensive Treatment for Intrahepatic Cholangiocarcinoma Patients from the Perspective of Tumor Heterogeneity].

Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma

Lymph node metastasis of intrahepatic cholangiocarcinoma: the present and prospect of detection and dissection

Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon

The Research Progress in Clinicopathological Characteristics and Treatment of Hepatitis B Virus-Associated Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma: New Insights in Pathology

Intrahepatic cholangiocarcinoma: current perspectives

Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma

Typing and Staging and Treatment of Intrahepatic Cholangiocarcinoma

Multidisciplinary approaches to intrahepatic cholangiocarcinoma

Conversion Therapy of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances

Systemic therapies for intrahepatic cholangiocarcinoma

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review